Myeloproliferative Disorders: Symptoms, Risk Factors and Treatment Options

Anthony M. Camden (Editor)

Series: Recent Advances in Hematology Research
BISAC: MED062000



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



Myeloproliferative disorders are a group of clonal haematological neoplasms characterised by proliferation of one or more cells of myeloid lineage. They are the result of acquired mutations in the progenitor cell leading to hyper proliferation or neoplastic expansion of more mature forms of myeloid cells. Cells retain their functional ability with some degree of defects and also lead to suppression of normal stem cells. The most common type of Myeloproliferative Neoplasms (MPN) can broadly be classified into BCR ABL positive (Chronic Myelogenous Leukemia) and BCR ABL negative Disorders (Polycythemia Vera PV, Essential Thrombocytosis ET and Primary Myelofibrosis PMF). There are other rare types which have relatively low incidence like chronic neutrophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis and myeloproliferative neoplasms unclassifiable.

These are the indolent type of haematological malignancies associated with marrow hypercellularity and organomegaly, with gradual progression to myelofibrosis or transformation to acute leukemias. During the dormant course of the BCR ABL negative MPN, they are more prone to thrombo-hemorrhagic complications and the treatment strategy is directed mostly to prevent complications. The past decade; therapies for BCR ABL positive disease (CML) have been a milestone achievement in keeping the disease in remission for many years, preventing major complications and halting the progression of the disease. This book discusses the classification, diagnosis and treatment of myeloproliferative diseases and provides insight on the symptoms and risk factors involved in the diseases. (Imprint: Nova Biomedical )


Chapter 1 - Myeloproliferative Diseases: Classification, Diagnosis and Treatment (pp. 1-54)
Farhan Mohammad, F.N.U. Vikram, M.D., Wajeeha Saeed, M.D., George Everett, M.D., Amar Lal, M.D., and Muhammad Rizwan Sardar, M.D. (Staten Island University Hospital, Staten Island, NY, USA, and others)

Chapter 2 - Histopathology and Diagnostic Approaches to the Myeloproliferative Neoplasms (pp. 55-74)
Christina Salazar, Sanjeev M. Balamohan, Patrick D. Millikan, Wendy H. Raskind and Melissa A. Kacena (Indiana University School of Medicine, Indianapolis, IN, USA, and others)

Chapter 3 - PCM1-JAK2 Myelodysplastic/ Myeloproliferative Neoplasms (pp. 75-98)
Elena Masselli, Marco Vitale and Franco Aversa (Clinical and Experimental Medicine, Unit of Hematology, University of Parma, Italy, and others)

Chapter 4 - Symptoms, Risk Factors and Treatment Options of Myeloproliferative Neoplasms (pp. 99-128)
Fabiola Attié de Castro, Ph.D., Sandra Mara Burin, Daniela Dover de Araujo, Ph.D., Natalia de Souza Nunes, Mariana Cristina Lima Souza, Cristiane Fernandes de Freitas Tavares, Ph.D., and Raquel Tognon Ribeiro, Ph.D. (Clinical Analyses, Toxicology and Food Sciences Department, School of Pharmaceutical Science of Ribeirão Preto-University of São Paulo, Ribeirão Preto, Brazil, and others)


You have not viewed any product yet.